{"organizations": [], "uuid": "2110d7bf0b086c6e0f71bb8f904bcce537d5aa0b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 10}, "facebook": {"likes": 35, "shares": 35, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s2.reutersmedia.net/resources/r/?m=02&d=20180103&t=2&i=1218957778&w=1200&r=LYNXMPEE0204E", "site_section": "https://www.reuters.com/finance/funds", "section_title": "Best Mutual Funds and ETFs | Reuters.com", "url": "https://www.reuters.com/article/us-pershing-sq-hldg-valeant-pharm-in/pershing-square-valeant-asked-to-appear-for-hearing-on-insider-trading-suit-idUSKBN1ES06Z", "country": "US", "domain_rank": 408, "title": "Pershing Square, Valeant asked to appear for hearing on insider trading suit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T12:25:00.000+02:00", "replies_count": 0, "uuid": "2110d7bf0b086c6e0f71bb8f904bcce537d5aa0b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/us-pershing-sq-hldg-valeant-pharm-in/pershing-square-valeant-asked-to-appear-for-hearing-on-insider-trading-suit-idUSKBN1ES06Z", "ord_in_thread": 0, "title": "Pershing Square, Valeant asked to appear for hearing on insider trading suit", "locations": [], "entities": {"persons": [{"name": "valeant", "sentiment": "negative"}, {"name": "bill ackman", "sentiment": "none"}, {"name": "abinaya vijayaraghavan", "sentiment": "none"}, {"name": "amrutha gayathri", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "pershing square", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}, {"name": "central district of california", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "valeant pharmaceuticals international inc", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "none"}, {"name": "pershing square capital management", "sentiment": "none"}, {"name": "u.s. district court", "sentiment": "none"}, {"name": "allergan", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - A U.S. court on Tuesday asked Valeant Pharmaceuticals International Inc ( VRX.TO ) and activist investor Bill Ackman’s Pershing Square ( PSH.AS ) to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit.\nThe hearing, set for Jan. 16, comes after Pershing Square and Valeant last week decided to pay $290 million to settle the lawsuit that accused them of insider trading before bidding for Allergan Plc ( AGN.N ) in 2014.\nThe lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited $51 billion bid for Allergan.\nThe court has “substantial questions regarding whether the settlement amount is reasonable and fair,” according to documents filed in the U.S. District Court, Central District of California.\n“Today’s order is a mandated step in the settlement process,” a Valeant spokeswoman said in an email to Reuters. “We believe the settlement is fair, reasonable and adequate, and we look forward to explaining our position to the Court.”\nPershing Square could not be reached for comment outside regular business hours.\nReporting by Abinaya Vijayaraghavan in Bengaluru; Editing by Amrutha Gayathri\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-03T12:25:00.000+02:00", "crawled": "2018-01-03T06:28:57.000+02:00", "highlightTitle": ""}